Review of the article „Enhanced oral bioavailability of Ibrutinib encapsulated poly (lactic-co-glycolic acid) nanoparticles: Pharmacokinetic evaluation in rats“, verified by Publons, Web of Science
Чланак у часопису (Рецензирана верзија)
Метаподаци
Приказ свих података о документуАпстракт
Abstract
Background: The poor oral bioavailability of newly discovered chemical entities and marketed formulations are usually related with poor aqueous solubility or poor permeability, leading to failure of drug either in drug development phases or therapeutic failure in clinical setting. However, advancement in drug formulations and drug delivery technologies has enabled the scientists to improve the bioavailability of formulations by enhancing solubility or permeability.
Objective: This study reports the enhancement of oral bioavailability of ibrutinib (IBR), a poorly soluble anticancer drug in Wistar Albino rats.
Method: Ibrutinib loaded nanoparticles were formulated by nanoprecipitation method by utilizing poly lactide co-glycolide (PLGA) as a safe biodegradable and biocompatible polymer and poloxamer or pluronic 127 as stabilizer. Animals were administered with 10 mg/kg of IBR suspension or equivalent amount of IBR loaded nanoparticles. Plasma samples were extracted and ana...lyzed by state of the art UPLC-MS/MS technique. Pharmacokinetic (PK) parameters and bioavailability were calculated by non-compartmental analysis.
Results: There was approximately 4.2-fold enhancement in the oral bioavailability of ibrutinib-loaded nanoparticles as compared with pure ibrutinib suspension. The maximum plasma concentration (Cmax; 574.31 ± 56.20 Vs 146.34 ± 5.37 ng/mL) and exposure (AUC; 2291.65 ± 263.83 Vs 544.75 ± 48.33 ng* h/mL) of ibrutinib loaded nanoparticles were significantly higher than those exhibited by pure ibrutinib suspension.
Conclusion: The outcomes of present study suggested the potential of PLGA nanoparticles in the enhancement of in bioavailability and therapeutic efficacy of ibrutinib.
Извор:
Current Pharmaceutical Analysis, 2019, 1/BMS-CPA-2018-284-21Колекције
Институција/група
Mašinski fakultetTY - JOUR AU - Jovanović, Tamara PY - 2019 UR - https://machinery.mas.bg.ac.rs/handle/123456789/5984 AB - Abstract Background: The poor oral bioavailability of newly discovered chemical entities and marketed formulations are usually related with poor aqueous solubility or poor permeability, leading to failure of drug either in drug development phases or therapeutic failure in clinical setting. However, advancement in drug formulations and drug delivery technologies has enabled the scientists to improve the bioavailability of formulations by enhancing solubility or permeability. Objective: This study reports the enhancement of oral bioavailability of ibrutinib (IBR), a poorly soluble anticancer drug in Wistar Albino rats. Method: Ibrutinib loaded nanoparticles were formulated by nanoprecipitation method by utilizing poly lactide co-glycolide (PLGA) as a safe biodegradable and biocompatible polymer and poloxamer or pluronic 127 as stabilizer. Animals were administered with 10 mg/kg of IBR suspension or equivalent amount of IBR loaded nanoparticles. Plasma samples were extracted and analyzed by state of the art UPLC-MS/MS technique. Pharmacokinetic (PK) parameters and bioavailability were calculated by non-compartmental analysis. Results: There was approximately 4.2-fold enhancement in the oral bioavailability of ibrutinib-loaded nanoparticles as compared with pure ibrutinib suspension. The maximum plasma concentration (Cmax; 574.31 ± 56.20 Vs 146.34 ± 5.37 ng/mL) and exposure (AUC; 2291.65 ± 263.83 Vs 544.75 ± 48.33 ng* h/mL) of ibrutinib loaded nanoparticles were significantly higher than those exhibited by pure ibrutinib suspension. Conclusion: The outcomes of present study suggested the potential of PLGA nanoparticles in the enhancement of in bioavailability and therapeutic efficacy of ibrutinib. T2 - Current Pharmaceutical Analysis T1 - Review of the article „Enhanced oral bioavailability of Ibrutinib encapsulated poly (lactic-co-glycolic acid) nanoparticles: Pharmacokinetic evaluation in rats“, verified by Publons, Web of Science EP - 21 SP - 1/BMS-CPA-2018-284 DO - 1573-4129 ER -
@article{ author = "Jovanović, Tamara", year = "2019", abstract = "Abstract Background: The poor oral bioavailability of newly discovered chemical entities and marketed formulations are usually related with poor aqueous solubility or poor permeability, leading to failure of drug either in drug development phases or therapeutic failure in clinical setting. However, advancement in drug formulations and drug delivery technologies has enabled the scientists to improve the bioavailability of formulations by enhancing solubility or permeability. Objective: This study reports the enhancement of oral bioavailability of ibrutinib (IBR), a poorly soluble anticancer drug in Wistar Albino rats. Method: Ibrutinib loaded nanoparticles were formulated by nanoprecipitation method by utilizing poly lactide co-glycolide (PLGA) as a safe biodegradable and biocompatible polymer and poloxamer or pluronic 127 as stabilizer. Animals were administered with 10 mg/kg of IBR suspension or equivalent amount of IBR loaded nanoparticles. Plasma samples were extracted and analyzed by state of the art UPLC-MS/MS technique. Pharmacokinetic (PK) parameters and bioavailability were calculated by non-compartmental analysis. Results: There was approximately 4.2-fold enhancement in the oral bioavailability of ibrutinib-loaded nanoparticles as compared with pure ibrutinib suspension. The maximum plasma concentration (Cmax; 574.31 ± 56.20 Vs 146.34 ± 5.37 ng/mL) and exposure (AUC; 2291.65 ± 263.83 Vs 544.75 ± 48.33 ng* h/mL) of ibrutinib loaded nanoparticles were significantly higher than those exhibited by pure ibrutinib suspension. Conclusion: The outcomes of present study suggested the potential of PLGA nanoparticles in the enhancement of in bioavailability and therapeutic efficacy of ibrutinib.", journal = "Current Pharmaceutical Analysis", title = "Review of the article „Enhanced oral bioavailability of Ibrutinib encapsulated poly (lactic-co-glycolic acid) nanoparticles: Pharmacokinetic evaluation in rats“, verified by Publons, Web of Science", pages = "21-1/BMS-CPA-2018-284", doi = "1573-4129" }
Jovanović, T.. (2019). Review of the article „Enhanced oral bioavailability of Ibrutinib encapsulated poly (lactic-co-glycolic acid) nanoparticles: Pharmacokinetic evaluation in rats“, verified by Publons, Web of Science. in Current Pharmaceutical Analysis, 1/BMS-CPA-2018-284-21. https://doi.org/1573-4129
Jovanović T. Review of the article „Enhanced oral bioavailability of Ibrutinib encapsulated poly (lactic-co-glycolic acid) nanoparticles: Pharmacokinetic evaluation in rats“, verified by Publons, Web of Science. in Current Pharmaceutical Analysis. 2019;:1/BMS-CPA-2018-284-21. doi:1573-4129 .
Jovanović, Tamara, "Review of the article „Enhanced oral bioavailability of Ibrutinib encapsulated poly (lactic-co-glycolic acid) nanoparticles: Pharmacokinetic evaluation in rats“, verified by Publons, Web of Science" in Current Pharmaceutical Analysis (2019):1/BMS-CPA-2018-284-21, https://doi.org/1573-4129 . .